Trials
2 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alopecia Areata
- Main trialPhase 2
- “The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.”In the company’s words, NCT07311564 on ClinicalTrials.gov
Other drugs for Alopecia Areata
- RitlecitinibPfizer · Phase 3
- DeuruxolitinibSun Pharma · Phase 3
- UpadacitinibAbbVie · Phase 3
- ALD-102Aldena Therapeutics · Phase 1/2
- SYHX1901CSPC · Phase 2
- LY4005130Eli Lilly · Phase 2
Coming up1
- 23 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 23 Jun 2027 | A Study of LAD603 in Adults With Alopecia Areata | |
| Phase 1Completed | 11 May 2025 | A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects | |
| Phase 2Authorised | not given | A Phase 2, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of LAD603 in patients with systemic lupus erythematosus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026